Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063077 | 0.87 | — | — | |
| SCHEMBL11191940 | 0.87 | — | — | |
| Bromide SCHEMBL3074212 | 0.85 | — | — | |
| Bromide SCHEMBL1843806 | 0.85 | — | — | |
| Bromide SCHEMBL7204393 | 0.85 | — | — | |
| Bromide SCHEMBL5667040 | 0.85 | — | — | |
| Sulfuric Acid SCHEMBL31317487 | 0.83 | NOS3 (0.75) | CYP2D6KDM4EBLMCYP2C19NPSR1 | |
| SCHEMBL8692894 | 0.76 | NOS3 (0.50) | CYP2D6KDM4EBLMCYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL2830996 | 0.71 | KDM4E (0.52) | CYP2D6KDM4EBLMCYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL22347074 | 0.71 | BLM (1.00) | CYP2D6KDM4EBLMCYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20070224671-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20040220239-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6489308-B1 | ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF | TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION | 2002-12-03 | — | — | US | disclosed |